APPLICABILITY OF CURRENT PROGNOSTICATION MODELS FOR MDS PATIENTS WITH DDX41 MUTATION

EHA Library, Nadia Toumeh, 4160044

CLINICAL CHARACTERISTICS AND LONG-TERM TREATMENT OUTCOME IN CHILDHOOD MYELODYSPLASTIC NEOPLASM: A NATIONWIDE POPULATION-BASED STUDY IN KOREA

EHA Library, Jung Yoon, 4160045

EFFICACY AND SAFETY OF LUSPATERCEPT AND ERYTHROPOIESIS-STIMULATING AGENT IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS WITH RING SIDEROBLASTS (MDS-RS): A MULTICENTER REAL-LIFE STUDY.

EHA Library, Thibault Comont, 4160046

CLINICAL AND MOLECULAR CHARACTERIZATION OF ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES AND OUTCOMES WITH VENETOCLAX-BASED THERAPY

EHA Library, Alexandre Bazinet, 4160047

PERIPHERAL BLOOD NGS TO INVESTIGATE UNEXPLAINED CYTOPENIAS: EVALUATING A RISK-STRATIFIED APPROACH TO REDUCE BONE MARROW BIOPSIES

EHA Library, Grace Collord, 4160048

ALLO-HSCT IN MDS-H AND MDS-LB PATIENTS: FAVORABLE OUTCOMES DESPITE IPSS-M HIGHER-RISK AND TRANSFUSION DEPENDENCE

EHA Library, Wenjing Guo, 4160049

CPX-351 FOR TRANSPLANT ELIGIBLE, HIGHER RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES: MOLECULAR RESPONSES AND LONG-TERM FOLLOW-UP

EHA Library, Veronica Guerra, 4160050

IMPROVEMENTS IN HEMATOLOGICAL PARAMETERS AND QUALITY OF LIFE (QOL) WITH ELRITERCEPT: RESULTS FROM AN ONGOING PHASE 2 TRIAL IN PARTICIPANTS WITH LOWER-RISK (LR) MYELODYSPLASTIC NEOPLASMS (MDS)

EHA Library, Aristoteles Giagounidis, 4160051

FLT3 MUTATIONS IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A MULTI-CENTER ANALYSIS

EHA Library, Juan Jose Rodriguez Sevilla, 4160052

INCREASED DURATION OF TIME WITHOUT TRANSFUSION RELIANCE FOR PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH IMETELSTAT VERSUS PLACEBO IN THE IMERGE TRIAL

EHA Library, Esther N. Oliva, 4160053

ERYTHROID STIMULATING AGENTS IN VEXAS SYNDROME: A MULTICENTER RETROSPECTIVE STUDY OF AN ITALIAN VEXAS COHORT

EHA Library, Elisa Diral, 4160054

INFLUENCE ANALYSIS OF TP53 AND SETBP1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

EHA Library, Wang xianwei, 4160055

ROLE OF PRE-TRANSPLANT MOLECULAR REMISSION ON OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANT IN MYELODYSPLASTIC SYNDROMES

EHA Library, Sudhamsh Reddy Desai, 4160056

PATIENT-DERIVED EXPANDED POTENTIAL STEM CELLS FROM PNH DEMONSTRATE GLYCOSYL-PHOSPHATIDYL INOSITOL ANCHORED PROTEIN AS A CRITICAL REGULATOR IN HEMATOPOIETIC DEVELOPMENT AND DIFFERENTIATION

EHA Library, Rong Fu, 4160057

IN VIVO EPIGENETIC CRISPR SCREENING IDENTIFIES SMARCA4 AS A CRITICAL TARGET FOR AUTOIMMUNE BONE MARROW FAILURE

EHA Library, Linzhu Tian, 4160058

GENOTYPE-PHENOTYPE ANALYSIS IN GATA2 DEFICIENCY: INSIGHTS FROM 901 INDIVIDUALS

EHA Library, Lili Kotmayer, 4160059

DIHYDROARTEMISININ MODULATES CD4+ T CELL DIFFERENTIATION THROUGH NOTCH SIGNALING IN APLASTIC ANEMIA

EHA Library, Jing Guan, 4160060

THE ROLE OF NK CELLS IN THE IMMUNE ESCAPE PATHOGENESIS OF PATIENTS WITH CLASSICAL PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA

EHA Library, Rong Fu, 4160061

HEROMBOPAG COULD RESTORE HEMATOPOIETIC AND IMMUNE HOMEOSTASIS OF APLASTIC ANEMIA PATIENTS BY REMODELING BONE MARROW MACROPHAGE POLARIZATION VIA ACTIVATING THE PI3K/AKT PATHWAY

EHA Library, Chenyuan Li, 4160062

COMPREHENSIVE MULTIPROTEOMIC ANALYSIS REVEALS AN INFLAMMATORY PHENOTYPE WITH A TH1/17 AXIS IN IMMUNE APLASTIC ANEMIA

EHA Library, Audrey Le Floc'h, 4160063

MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM THE BONE MARROW OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA COMBINED WITH BONE MARROW FAILURE REVEAL PROFOUND CHANGES IN GENE EXPRESSION

EHA Library, Alena Dorofeeva, 4160064

AUTOIMMUNE NEUTROPENIA AND CHRONIC IDIOPATHIC NEUTROPENIA OF CHILDHOOD ARE ASSOCIATED WITH A LOWER PERCENTAGE OF T REGULATORY CELLS

EHA Library, Konstantina Toutoudaki, 4160065

ZALTENIBART, AN ALTERNATIVE PATHWAY OF COMPLEMENT MASP-3 INHIBITOR, IMPROVED HEMATOLOGIC PARAMETERS IN PNH PATIENTS WITH PERSISTENT ANEMIA ON RAVULIZUMAB: ADJUNCTIVE AND MONOTHERAPY TREATMENT PHASES

EHA Library, Morag Griffin, 4160066

THE 2-YEAR SAFETY AND EFFICACY OF IPTACOPAN MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) FROM APPLY- AND APPOINT-PNH STUDIES WHO ENTERED THE ROLL-OVER EXTENSION PROGRAM (REP)

EHA Library, Antonio Risitano, 4160067

EFFICACY AND SAFETY OF POZELIMAB PLUS CEMDISIRAN VERSUS RAVULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA WHO ARE NAÏVE TO COMPLEMENT INHIBITION

EHA Library, Christopher Patriquin, 4160068

CLONAL HEMATOPOIESIS IN SEVERE APLASTIC ANEMIA AND ITS CLINICAL SIGNIFICANCE-ANALYSES OF MUTATIONS IN MYELOID MALIGNANCY-RELATED GENES AND HLA GENES, AS WELL AS LOSS OF HETEROZYGOSITY (LOH) OF HLA

EHA Library, Kuojui Sun, 4160069

2-YEAR EFFICACY AND SAFETY IN PATIENTS (PTS) WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WHO SELF-ADMINISTERED CROVALIMAB (CROVA) IN THE PHASE III RANDOMIZED COMMODORE 2 TRIAL

EHA Library, Alexander Röth, 4160070

EFFICACY AND SAFETY OF AVATROMBOPAG IN RELAPSED OR REFRACTORY SEVERE APLASTIC ANAEMIA: RESULTS OF THE DIAAMOND-AVA-NEXT TRIAL

EHA Library, Zoe McQuilten, 4160071

DEVELOPMENT OF DATA-DRIVEN MACHINE LEARNING ALGORITHMS TO HELP DIFFERENTIAL DIAGNOSIS BETWEEN INHERITED AND ACQUIRED BONE MARROW FAILURE SYNDROMES

EHA Library, Marta Bortolotti, 4160072

SUSTAINED LONG-TERM CONTROL OF TERMINAL COMPLEMENT ACTIVITY WITH RAVULIZUMAB OR DANICOPAN ADD-ON TO RAVULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Christopher Patriquin, 4160073

ELTROMBOPAG RESTORES T CELL HOMEOSTASIS IN APLASTIC ANEMIA BY MODULATING OXPHOS AND ROS LEVELS

EHA Library, Rong Fu, 4160074

DIAMOND-BLACKFAN ANEMIA SYNDROME BASED ON SPLICE-SITE VARIANTS IN RPS7 IS CHARACTERIZED BY RELATIVELY MILD ANEMIA, CRANIOFACIAL ABNORMALITIES, AND A SUSPECTED HIGH CANCER RISK.

EHA Library, Evangelia Kiakou, 4160075

ADDING HETROMBOPAG TO CYCLOSPORINE FOR FIRST-LINE TREATMENT OF PATIENTS WITH NON-SEVERE APLASTIC ANEMIA: A PHASE 2 MULTI-CENTER CLINICAL STUDY

EHA Library, Lele Zhang, 4160076

REAL-WORLD OUTCOMES AND CLINICAL BURDEN OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Talha Munir, 4160077

EFFECTIVENESS AND SAFETY OF IPTACOPAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH PERSISTENT ANEMIA AFTER C5 INHIBITION: THE REAL-WORLD EXPERIENCE OF THE FRENCH EARLY ACCESS PROGRAM

EHA Library, Régis Peffault de Latour, 4160078

EARLY RESPONSE IN COMPLEMENT INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN IN THE PHASE 3 PRINCE TRIAL

EHA Library, Austin Kulasekararaj, 4160079

APPLICATION OF MACHINE LEARNING IN THE DIAGNOSTIC WORK-UP OF CHRONIC IDIOPATHIC NEUTROPENIA IN ADULTS

EHA Library, Grigorios Tsaknakis, 4160080

CSFR3 MUTATION IN CONGENITAL NEUTROPENIA A LONG STORY: DATA FROM THE ITALIAN REGISTRY

EHA Library, Francesco Pegoraro, 4160081

REAL-WORLD RETROSPECTIVE ANALYSIS OF PEGCETACOPLAN EFFECTIVENESS IN PATIENTS FROM CEE COUNTRIES WITH PNH AND NO OPTIMAL RESPONSE TO C5 INHIBITORS

EHA Library, Łukasz Szukalski, 4160082

INTERIM ANALYSIS OF THE ONGOING COMPLETE STUDY ON THE REAL-WORLD EFFECTIVENESS OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

EHA Library, Régis Peffault de Latour, 4160083

INHERITED BONE MARROW FAILURE DUE TO GATA2 GENE MUTATION WITH A PREDISPOSITION TO MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA

EHA Library, Mariia Vasileva, 4160084

VEXINATIONS: A MULTICENTER RETROSPECTIVE STUDY ON VACCINATIONS IN VEXAS SYNDROME

EHA Library, Gregorio Maria Bergonzi, 4160085

DEVELOPMENT OF A PREDICTIVE MODEL FOR ADVERSE MATERNAL AND PERINATAL OUTCOMES IN PREGNANT WOMEN WITH APLASTIC ANAEMIA

EHA Library, Qiuyu Guo, 4160086

PROTEOMIC LANDSCAPE OF CASTLEMAN DISEASE REVEALS THE IRF4-WFS1 AXIS DRIVES PROGRESSION VIA PLASMA CELL DIFFERENTIATION AND SURVIVAL

EHA Library, Peng Liu, 4160087

LRP8-DEPENDENT CHOLESTEROL METABOLISM MODULATES MTORC1 SIGNALING AND APOPTOTIC PATHWAYS IN MULTIPLE MYELOMA

EHA Library, Yue Wang, 4160088

AGE-ASSOCIATED MACROPHAGE POLARIZATION TO AN M2 PHENOTYPE DRIVES MYELOMA PROLIFERATION IN THE AGED BONE MARROW BY LOSS OF TUMOR-ASSOCIATED PHAGOCYTOSIS

EHA Library, Dominic Fowler-Shorten, 4160089

IMMUNE BIOMARKERS OF INCREASED RISK OF INFECTION IN MULTIPLE MYELOMA (MM)

EHA Library, Aintzane Zabaleta, 4160090

DISRUPTION OF NEAT1 DEPENDENT GENE EXPRESSION PROGRAM UNCOVERS NOVEL TARGETABLE VULNERABILITIES IN MULTIPLE MYELOMA.

EHA Library, Noemi Puccio, 4160091

IBERDOMIDE (IBER) TREATMENT ENHANCES MANUFACTURED CAR T CELL EXPANSION AND FUNCTIONALITY AND IS IMMUNOSTIMULATORY IN PATIENTS POST-CAR T CELL THERAPY

EHA Library, Adolfo Aleman, 4160092

CD70/CD27 SIGNALING PROMOTES CLONAL PLASMA CELL EXPANSION IN MULTIPLE MYELOMA AND REPRESENTS A PROMISING THERAPEUTIC TARGET

EHA Library, Maxime Boy, 4160093

SINGLE CELL RNA AND WHOLE GENOME SEQUENCING ANALYSIS REVEAL DISTINCT IMMUNE AND GENOMIC SIGNATURES IN WM PATIENTS RESISTANT TO IBRUTINIB THERAPY

EHA Library, Tina Bagratuni, 4160094

RADIOMICS-BASED RESPONSE PREDICTION IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA

EHA Library, Guneet Janda, 4160095

SELINEXOR POTENTIATES ANTIBODY-DEPENDENT CELLULAR-CYTOTOXICITY (ADCC) AND CAR-NK CELL ACTIVATION AGAINST MULTIPLE MYELOMA CELLS VIA DOWNREGULATION OF HLA-E

EHA Library, Matthew Blunt, 4160096

PRECLINICAL ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMBINATION STRATEGIES WITH T CELL BISPECIFICS AND DARATUMUMAB TO SUPPORT OPTIMIZATION OF CLINICAL BENEFIT IN MYELOMA PATIENTS

EHA Library, Vicki Plaks, 4160097

DIFFERENTIATING BETWEEN MM-LIKE AND MGUS-LIKE SMOLDERING MYELOMA

EHA Library, Anil Aktas Samur, 4160098

A NOVEL HYPOXIA GENE SIGNATURE FROM THE HOVON-65/GMMG-HD4 PHASE 3 STUDY PROGNOSTIC OF SURVIVAL AND ASSOCIATED WITH IMMUNE SUPPRESSION IN THE TUMOR MICROENVIRONMENT

EHA Library, Catharina Van Elssen, 4160099

IFN-RESPONSIVE STROMAL CELLS DRIVE NON-IMMUNE BONE MARROW NICHE ALTERATIONS IN MULTIPLE MYELOMA PROGRESSION AND VRD TREATMENT RESPONSE

EHA Library, Miguel Cócera, 4160100

ROLE AND MECHANISM OF MULTIPLE MYELOMA CELLS IN REGULATING MACROPHAGE POLARIZATION AND THE ANTITUMOR EFFECT VIA ENO1

EHA Library, Zhaoyun Liu, 4160101

PROGNOSTIC SIGNIFICANCE AND MOLECULAR FUNCTION OF PSMD10 AS A REGULATOR OF PROTEOSTASIS IN MULTIPLE MYELOMA

EHA Library, Zuzanna Tracz-Gaszewska, 4160103

MULTIOMIC IMMUNE BIOMARKERS OF MRD PERSISTENCE IN MULTIPLE MYELOMA

EHA Library, Maria Speciale, 4160104

EXOSOME-DERIVED CIRCCOG5,AS A NEW PROGNOSTIC INDICATOR OF MBD, AGGRAVATED OSTEOLYTIC LESIONS BY CIRCCOG5 / MIR-625-3P / RANKL AXIS

EHA Library, Xing Cui, 4160105

BONE MARROW BREAKOUT LESIONS ACT AS KEY SITES FOR TUMOR-IMMUNE CELL DIVERSIFICATION AND EXHAUSTION IN MULTIPLE MYELOMA

EHA Library, Llorenç Solé-Boldo, 4160106

STUDY ON THE INHIBITION OF LACTATE METABOLISM IN MULTIPLE MYELOMA CELLS TO ENHANCE THE ANTI-TUMOR EFFECT OF BCMA CAR-T CELLS

EHA Library, Zhaoyun Liu, 4160107

EFFICACY AND SAFETY OUTCOMES IN PATIENTS (PTS) WITH RENAL IMPAIRMENT IN THE PHASE 3 DREAMM-7 AND DREAMM-8 TRIALS

EHA Library, Marcelo Pitombeira De Lacerda, 4160108

CARDIAC GLYCOSIDES INDUCE IMMUNOGENIC CELL DEATH IN MYELOMA CELLS AND ENHANCE THE EFFICACY OF THERAPEUTIC ANTIBODIES

EHA Library, Tomoyuki Nakamura, 4160109

MALIGNANT PLASMA CELL-DERIVED CCL2 REPROGRAM MACROPHAGE PROMOTING DISEASE PROGRESSION IN MULTIPLE MYELOMA BONE MARROW MICROENVIRONMENT

EHA Library, HongYan Zhao, 4160110

PROGNOSTIC VALUE AND MUTATIONAL PROFILE OF CIRCULATING CLONAL B CELLS IN WALDENSTRÖM MACROGLOBULINEMIA PATIENTS UNDERGOING IBRUTINIB THERAPY

EHA Library, Tina Bagratuni, 4160111

INHIBITION OF CARBONIC ANHYDRASE IX AS A NEW THERAPEUTIC STRATEGY IN MULTIPLE MYELOMA

EHA Library, Giorgia Gazzaroli, 4160112

COMPREHENSIVE STUDY OF P53 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS THROUGHOUT THE COMBINATION OF OMICS.

EHA Library, Cristina De Ramón Sánchez, 4160113

HIGH-DIMENSIONAL SPATIAL PROFILING OF THE BONE MARROW MICROENVIRONMENT IN MULTIPLE MYELOMA

EHA Library, Shiva Nickaria, 4160114

INTEGRATING OPTICAL GENOME MAPPING AND NEXT-GENERATION SEQUENCING IN A COHORT OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, David Martínez-Campuzano, 4160115

EXPLORATORY BIOMARKERS ASSOCIATED WITH TALQUETAMAB RESISTANCE AND RELAPSE IN THE MONUMENTAL-1 CHINA 400 COHORT BY DATA-DRIVEN UNSUPERVISED CLUSTERING ANALYSIS

EHA Library, Hongmei Xu, 4160116

APPLICATION OF SPATIAL TRANSCRIPTOMICS FOR ANALYZING MULTIPLE MYELOMA

EHA Library, Sandra Haingartner, 4160117

BRAIN MRI FINDINGS IN UNTREATED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

EHA Library, Wilma Barcellini, 4160118

THE NOVEL RECURRENT FUSION GENE DDX5-EEF1A1 SERVES AS A MOLECULAR BIOMARKER FOR PREDICTING DISEASE PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS.

EHA Library, Liu Hongchen, 4160119

MASS SPECTROMETRY ENABLES PRECISE MONITORING OF BISPECIFIC ANTIBODY THERAPY IN MULTIPLE MYELOMA

EHA Library, M Teresa Cedena, 4160120

GENOME-WIDE LOSS-OF-FUNCTION CRISPR SCREENS PINPOINT PSME1 AS DETERMINANT FOR CARFILZOMIB RESISTANCE IN MULTIPLE MYELOMA

EHA Library, Maja Jakobsen, 4160121

3D BIOMIMETIC MICROGEL PLATFORM FOR MULTIPLE MYELOMA: REPLICATING TUMOUR MICROENVIRONMENT ON CELL LINES AND PATIENT-DERIVED CELLS.

EHA Library, Maria Inmaculada Garcia-Briega, 4160122

PAEONIFLORIN AMELIORATES BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY BY RECTIFYING ABNORMAL INTERLEUKIN-6 SECRETION AND AUTOPHAGY LEVEL

EHA Library, Xing Cui, 4160123

DEGRADATION OF IKZF1 VIA E3 UBIQUITIN LIGASE X BY DNA DEMETHYLATING AGENTS IS A POTENTIAL THERAPEUTIC TARGET FOR MULTIPLE MYELOMA

EHA Library, Yuta Yamamoto, 4160124

SYSTEMIC DISSEMINATION AND RESPONSIVENESS TO CLINICALLY-USED THERAPEUTICS IS RECAPITULATED IN A CHICK EMBRYO XENOGRAFT MODEL OF MULTIPLE MYELOMA

EHA Library, Izabela Cymer, 4160125

PHASE 1, FIRST-IN-HUMAN STUDY OF ISB 2001: A BCMAXCD38XCD3-TARGETING TRISPECIFIC ANTIBODY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)—DOSE ESCALATION (DE) RESULTS.

EHA Library, Hang Quach, 4160126

CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) VERSUS ELOTUZUMAB-KRD IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: INITIAL RESULTS FOR 3-YEAR PROGRESSION-FREE SURVIVAL (PFS)

EHA Library, Stefan Knop, 4160127

UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN ALL-ORAL TREATMENT

EHA Library, Binod Dhakal, 4160128

LONG TERM EFFICACY AND SAFETY OF ETENTAMIG (ABBV-383), A B-CELL MATURATION ANTIGEN (BCMA) BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Muhamed Baljević, 4160129

MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) AND BORTEZOMIB (BORT) OR CARFILZOMIB (CFZ) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM THE CC-92480-MM-002 TRIAL

EHA Library, Irwindeep Sandhu, 4160130

OUTCOME OF EARLY INTERVENTION AT MRD PROGRESSION IN MULTIPLE MYELOMA PATIENTS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION: : A RETROSPECTIVE ANALYSIS

EHA Library, Juan Li, 4160131

BIRTAMIMAB SAFETY IN AL AMYLOIDOSIS PATIENT SUBGROUPS: MAYO STAGE I-III VS STAGE IV AND PREVIOUSLY TREATED PATIENTS RECEIVING MONOTHERAPY VS NEWLY DIAGNOSED PATIENTS WITH CONCOMITANT STANDARD OF CARE

EHA Library, Ashutosh Wechalekar, 4160132

DREAMM-8: MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE VS STANDARD-OF-CARE REGIMEN

EHA Library, Meletios Dimopoulos, 4160133

ISA-VRD IMPROVES OUTCOMES IN HIGH-RISK (HR) NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA (NDMM TI) USING THE IMS/IMWG CONSENSUS HR DEFINITION: RESULTS FROM THE BENEFIT PHASE 3 TRIAL (IFM 2020-05)

EHA Library, Jill Corre, 4160134

UPDATED RESULTS FROM PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS POMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 4160135

ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-VRD) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): OUTCOMES IN PATIENTS WITH 1Q21+ STATUS IN THE PHASE 3 IMROZ STUDY

EHA Library, Meletios Dimopoulos, 4160136

CHALLENGING THE CONCEPT OF FUNCTIONAL HIGH-RISK MYELOMA THROUGH ADVANCED TRANSCRIPTIONAL AND GENETIC PROFILING.

EHA Library, Sina A Beer, 4160137

DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE/TRANSPLANT-DEFERRED NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS

EHA Library, Nizar J Bahlis, 4160138

PROSPECTIVE FUNCTIONAL BONE DISEASE EVALUATION OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITH COMBINED USE OF (18)F-FDG-PET/CT AND WHOLE-BODY DIFFUSION WEIGHTED MAGNETIC RESONANCE

EHA Library, Marco Talarico, 4160139

EXTENDED DOSING SCHEDULE OF BELANTAMAB MAFODOTIN IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: THE PHASE 1/2 BELADRD STUDY

EHA Library, Evangelos Terpos, 4160140

A MULTICENTER PHASE 2 STUDY DESIGNED TO OPTIMIZED THE SCHEDULE OF BELANTAMAB MAFODOTIN PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Tereza Popková, 4160141

CYTOPENIAS AND INFECTIONS FOLLOWING CILTACABTAGENE AUTOLEUCEL IN HEAVILY-PRETREATED RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Danai Dima, 4160142

OUTCOMES OF MYELOMA PATIENTS WITH DEL 17P WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION IN EBMT CENTRES BETWEEN 2016 AND 2022

EHA Library, Patrick Hayden, 4160143

IBERDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (IBERVD) IN TRANSPLANT-INELIGIBLE (TNE) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED RESULTS FROM THE CC-220-MM-001 TRIAL

EHA Library, Darrell White, 4160144